Published: 2 June 2022

Publications

Recent approvals: New active ingredients or new indications

Published 2 June 2022
Prescriber Update 43(2): 21
June 2022

For the period 16 January to 15 April 2022.

Recent approvals of medicines with new active ingredients

Trade name (active ingredient) Dose form and strength(s) Therapeutic area
Ajovy (fremanezumab) Solution for injection
225 mg/1.5 mL
Migraine
Evrysdi (risdiplam) Powder for oral solution
750 mcg/mL
Spinal muscular atrophy
Zejula (niraparib) Capsule
100 mg
Epithelial ovarian, fallopian tube, or primary peritoneal cancer
Nuvaxovid* (COVID-19 vaccine with Matrix-M adjuvant) Solution for injection
10 mcg/mL
COVID-19 prevention
Paxlovid* (nirmatrelvir; ritonavir) Film-coated tablet
150 mg/100 mg
COVID-19 treatment
Lagevrio* (molnupiravir) Capsule
200 mg
COVID-19 treatment

* Provisional approval.

Approved medicines with new indications

Trade Name (active ingredient) Dose form and strength(s) New therapeutic area(s)
Lenvima (lenvatinib) Capsule
4 mg
10 mg
Endometrial carcinoma
Xolair (omalizumab) Solution for injection
75 mg
150 mg
Chronic rhinosinusitis with nasal polyps
Yervoy (ipilimumab) Concentrate for injection
50 mg/10 mL
200 mg/40 mL
Malignant pleural mesothelioma
Winglore (ipilimumab) Concentrate for injection
50 mg/10 mL
200 mg/40 mL
Malignant pleural mesothelioma
Keytruda (pembrolizumab) Concentrate for infusion
25 mg/mL (100 mg/4 mL)
Endometrial carcinoma
Opdivo (nivolumab) Concentrate for infusion
40 mg/4 mL
100 mg/10 mL
Malignant pleural mesothelioma
Oesophageal squamous cell carcinoma


See the Medsafe website for:

Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /